GB10 / Shenzhen Kexing Pharma - LARVOL DELTA

Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ('Shenzhen Kexing'), a wholly-owned subsidiary of Kexing Biopharm. (The Manila Times) - "Designed to treat neovascular age-related macular degeneration (nAMD), the progress of GB10 marks a significant milestone in the Company's accelerating innovative drug R&D pipeline."

Trial status • Age-related Macular Degeneration